Insulin-like growth factor I, IGF-I, is a hormone that is found in the blood and contributes to, among other things, growth and bone mass. The levels of this hormone are higher in people who exercise regularly and those with good health.
Scientists at the Sahlgrenska Academy have shown for the first time that high levels of this hormone are associated with better long-term recovery after a stroke. The study has been presented in an article in the Journal of Clinical Endocrinology and Metabolism.“This study is interesting for two reasons. The first is that we show that a hormone is associated with improved long-term recovery, and thus there is still the prospect of improvement – even after three months after the stroke. The second is that levels of this hormone are known to be elevated in those who exercise often”, says Associate Professor David Åberg at the Sahlgrenska Academy, who has led the study in collaboration with Professor Jörgen Isgaard.
“It is, however, important to add that the levels of IGF-I are controlled also by other factors such as other growth hormones, heredity and nutrition”, emphasises David Åberg.
The study is based on 407 patients who are participating in the SAHLSIS study at the Sahlgrenska Academy, in which people aged 18-70 years who are affected by stroke are followed up for two years after the event. SAHLSIS is an acronym for “The Sahlgrenska Academy Study on Ischemic Stroke”.
Scientists have measured the levels of IFG-I in these 407 patients and seen that increased levels are associated with better recovery, when the degree of recovery is determined between 3 and 24 months after the stroke. Previous research (Bondanelli et al) has also shown a positive effect of high IGF-I levels in the early phase after a stroke, while the scientists at the Sahlgrenska Academy have now demonstrated that the positive effects on recovery remain long after the stroke event.
These results pave the way for further studies on whether drug treatments that raise IGF-I levels can improve long-term recovery after stroke. David Åberg believes that two avenues are open: either to treat with IGF-I, or to treat with the better known growth hormone (GH). This can stimulate the body’s own production of IGF-I.
“Of course, these possibilities must be tested in carefully constructed clinical trials, so that we discover any undesired effects that must be considered. This is particularly true during the acute phase of a stroke, while treatment during the recovery phase is probably easier and has greater benefit”, says David Åberg.The journal: The Journal of Clinical Endocrinology and Metabolism
Helena Aaberg | idw
Could this protein protect people against coronary artery disease?
17.11.2017 | University of North Carolina Health Care
Microbial resident enables beetles to feed on a leafy diet
17.11.2017 | Max-Planck-Institut für chemische Ökologie
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
17.11.2017 | Physics and Astronomy
17.11.2017 | Health and Medicine
17.11.2017 | Studies and Analyses